Please log in to determine if you are eligible to purchase PT Programs.
HLA DISEASE ASSOCIATION-DRUG RISK - DADR2
DADR2
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Analyte
Challenges per Shipment
Number of Shipments
HLA-A*29:01
3
Two shipments per year
HLA-A*29:02
3
HLA-DQA1*04:01
3
HLA-DQA1*05:01
3
HLA-DQB1*03:02
3
HLA-DQB1*06:02
3
HLA-DRB1*03:01
3
HLA-DRB1*03:02
3
HLA-DRB1*04:02
3
HLA-DRB1*04:03
3
HLA-DRB1*04:06
3
HLA-DRB1*08:02
3
HLA-DRB1*08:04
3
HLA-DRB1*14:04
3
HLA-DRB1*14:05
3
HLA-DRB1*14:08
3
HLA-DRB1*15:01
3
HLA-DRB1*15:02
3
HLA-DQA1*02
3
HLA-DQA1*03
3
HLA-DQA1*05
3
HLA-DQB1*02:01
3
HLA-DQB1*02:02
3
Additional Information
This program will challenge the laboratory to accurately identify the presence or absence
of alleles associated with a variety of disease states (listed below) and/or the adverse
reactions to specific drugs.
Celiac disease
Narcolepsy
Pemphigus Vulgaris
Psoriasis
Antiglomerular basement membrane disease
Birdshot retinochoroidopathy
Idiopathic myopathy
Program Information
Three 0.1‑mL specimens, each containing 200 µg/mL of human DNA in media
Help